Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Stroke. 2013 Apr 23;44(6):1743–1747. doi: 10.1161/STROKEAHA.111.000427

Figure 3.

Figure 3

Western blot analysis of (A) p–GSK-3β/GSK-3β, (B) p–β-catenin/β-catenin, (C) claudin-3, and (D) claudin-5. Values are expressed as mean±SEM, normalized to sham. *P<0.05 compared with sham, †P<0.05 compared with vehicle, ‡P<0.05 compared with PHA-12 mg. N=5 per group. GSK-3β indicates glycogen synthase kinase-3β; and MLA, methyllycaconitine.